Anticoagulants

Bleeding Improved with Apixaban versus VKA

April 22, 2019

Bleeding in patients with nonvalvular atrial fibrillation and coronary syndrome was reduced by apixaban versus vitamin K antagonists.

Kidney Disease Patients May Not Be Getting OACs

April 22, 2019

Many kidney disease patients with atrial fibrillation are not treated with anticoagulation, increasing their risk of stroke.

Patients with Cognitive Impairment Less Likely to Get OACs

March 15, 2019

Study finds different anticoagulation treatment levels for patients with cognitive problems.

Two Studies Show Efficacy of Rivaroxaban, Other NOACs in Preventing Stroke

March 15, 2019

A meta-analysis of 95 studies indicates lower risk of stroke and intracranial hemorrhage.

Increased Risk of Blood Clots and Death Seen with Higher Dose Tofacitinib

February 26, 2019

Higher-dose tofacitinib linked to greater risk of pulmonary embolism in RA patients.

Cablivi for Acquired Thrombotic Thrombocytopenic purpura

February 18, 2019

What you need to know about the von Willebrand factor (vWF)-directed antibody fragment.

Study: DOACs Equal to or Better Than Warfarin

February 16, 2019

DOACs are as good as warfarin in preventing atrial fibrillation complications.

New Guidelines: NOACs Preferred Over Warfarin in AFib

February 16, 2019

Three cardiology groups now recommend using NOACs over warfarin in atrial fibrillation.

Racial Disparities Found in Oral Anticoagulant Prescription Patterns

January 14, 2019

Black patients with atrial fibrillation are less likely to be treated with oral anticoagulants or DOACs.

Choice of Anticoagulant and Cotherapy with a PPI Affect Gastrointestinal Bleeding Risk

January 11, 2019

The risk of gastrointestinal bleeding appears to be highest with rivaroxaban and lowest with apixaban, but is reduced by cotherapy with proton pump inhibitors.

x